Clinical outcomes in patients with advanced epidermal growth factor receptor‐mutated non‐small‐cell lung cancer in South Western Sydney Local Health District
Epidermal growth factor receptor (EGFR)‐mutated non‐small‐cell lung cancer (NSCLC) is a subgroup of oncogene addicted lung cancer that predicts response to tyrosine kinase inhibitors (TKI). However, there is variability in response and survival outcomes in patients with EGFR mutation treated with TKI.
No Supplementary Data
No Article Media